Goodwin Procter LLP has advised Avalo Therapeutics. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has advised the underwriters. Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a...
Avalo Therapeutics Launches $430 Million Public Offering of Common Stock and Warrants
Larimar Therapeutics Launches $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Goodwin Procter LLP has advised Larimar Therapeutics, Inc., and Mintz has advised the underwriters. Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on complex rare diseases,...
Larimar Therapeutics Completes $69 Million Public Offering
Goodwin Procter has advised Larimar Therapeutics, Inc. on the offering, and Mintz has advised the underwriters. Larimar Therapeutics, Inc. (Nasdaq: LRMR) has completed a public offering...
Aditum Bio’s Formation of Celexor Bio
Goodwin Procter advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals. Celexor Bio is being formed in connection...
ReWalk Robotics’ $19 Million Acquisition of AlterG
Goodwin Procter acted as legal counsel to ReWalk, and Wilson Sonsini acted as legal counsel to AlterG. ReWalk Robotics Ltd. (Nasdaq: RWLK) announced closing of the...
Globus Medical’s $3.1 Billon Merger with NuVasive
Goodwin Procter advised Globus Medical on the deal. Globus Medical (NYSE: GMED) announced its definitive agreement with NUVASIVE (NASDAQ: NUVA) to combine in an all-stock transaction. Under...
Societal CDMO’s $35.6 Million Underwritten Public Offerings
Troutman Pepper advised Societal CDMO, Inc. on the deal. Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing...
iECURE’s $65 Million Series A-1 Financing
Troutman Pepper advised iECURE on the deal. iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies...
Larimar Therapeutics’ $80.5 Million Shares Offering
Troutman Pepper advised Larimar Therapeutics, Inc. on the deal. Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,...
TELA Bio’s Shares Offering
Troutman Pepper advised TELA Bio on the deal. TELA Bio announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common...
Center for Breakthrough Medicines’ Partnership with University of Pennsylvania
Troutman Pepper advised Center for Breakthrough Medicines on the deal. Center for Breakthrough Medicines (CBM) has struck a landmark collaboration agreement with the University of Pennsylvania’s...
Century Therapeutics’ Collaboration with Bristol Myers Squibb
Troutman Pepper advised Century Therapeutics on the deal. Century Therapeutics (NASDAQ: IPSC) has announced a research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY)...